AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences.
| Event: | Morgan Stanley - 21stAnnual Global Healthcare Conference |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | H.C. Wainwright - 25thAnnual Global Investment Conference |
| Format: | Corporate presentation by Eric Schoen, Chief Financial Officer |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | JonesTrading - 2023 Healthcare Summit |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Tuesday, October 10th, 2023 |
| Where: | Miami |
| Event: | Jefferies - Inaugural Biotech CNS/Neuro Summit |
| Format: | Fireside chat with management |
| Date: | Wednesday, October 11, 2023 |
| Where: | New York City |
A webcast or subsequent archived replay of Cassava Sciences’ participation in these events may be available, depending on the conference and other factors. If a webcast or replay becomes available, it may be accessed via the Investors section of Cassava Sciences’ website at: www.CassavaSciences.com.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$22.10 |
| Daily Change: | -0.05 -0.23 |
| Daily Volume: | 244,036 |
| Market Cap: | US$955.830M |
March 25, 2024 February 07, 2024 December 07, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
